TG Therapeutics Inc. (NASDAQ: TGTX) announced that patient enrollment has started in a Phase 3 clinical trial evaluating a subcutaneous ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE